Literature DB >> 26674450

Incidence of Sepsis and Mortality With Prior Exposure of HMG-COA Reductase Inhibitors in a Surgical Intensive Care Population.

James W Schurr1, Wenchen Wu, Alexandria Smith-Hannah, Candace J Smith, Rafael Barrera.   

Abstract

The anti-inflammatory properties of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may reduce the risk of developing sepsis in surgical intensive care patients and improve outcomes in those who do become septic. The objective of this study was to assess whether surgical intensive care unit (SICU) patients with prior exposure to HMG-CoA reductase inhibitors had a lower incidence of developing sepsis and improved outcomes. A retrospective cohort study was conducted. Patient demographic data, statin use, sequential organ failure assessment (SOFA) scores, vasopressor requirements, ventilator days, length of SICU stay, and mortality in septic patients were collected. Incidence of development of sepsis was determined using systemic inflammatory response syndrome criteria. Patients were grouped into cohorts based on whether they met the sepsis criteria and if they had previously received statins. Cohorts of patients who did and did not become septic with prior statin exposure were compared and an odds ratio was calculated to determine a protective effect. The setting was a SICU. The study comprised of 455 SICU patients and had no interventions. Among the 455 SICU patients, 427 patients were included for the final results. Patients receiving statins verses not receiving statins were similar in demographics. Previous statin exposure had a protective effect in the development of sepsis (9.77% on statins vs. 33.6% without statins; odds ratio 0.203, confidence interval 0.118-0.351). Of those patients who developed sepsis, there was a statistically significant decrease in 28-day mortality in patients with prior statin exposure (P = 0.0341). No statistical difference was noted in length of stay, vasopressor requirements, or days on mechanical ventilation. Prior exposure to statins may have a protective effect on the development of sepsis and decrease mortality in critically ill surgical patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26674450     DOI: 10.1097/SHK.0000000000000484

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  7 in total

Review 1.  Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials.

Authors:  Myura Nagendran; Daniel F McAuley; Peter S Kruger; Laurent Papazian; Jonathon D Truwit; John G Laffey; B Taylor Thompson; Mike Clarke; Anthony C Gordon
Journal:  Intensive Care Med       Date:  2016-12-21       Impact factor: 17.440

2.  Statin use is not associated with improved 30-day survival in patients undergoing surgery for colorectal cancer.

Authors:  Tina Fransgaard; Lau Caspar Thygesen; Ismail Gögenur
Journal:  Int J Colorectal Dis       Date:  2017-12-21       Impact factor: 2.571

3.  Effects of sepsis on the metabolism of sphingomyelin and cholesterol in mice with liver dysfunction.

Authors:  Jiaqi Li; Kun Xia; Mingdi Xiong; Xi Wang; Nianlong Yan
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

Review 4.  Metabolic Inflammatory Complex in Sepsis: Septic Cachexia as a Novel Potential Therapeutic Target.

Authors:  Masao Kaneki
Journal:  Shock       Date:  2017-12       Impact factor: 3.454

5.  Statins in patients with sepsis and ARDS: is it over? We are not sure.

Authors:  Danny McAuley; Pierre-Emmanuel Charles; Laurent Papazian
Journal:  Intensive Care Med       Date:  2016-10-17       Impact factor: 17.440

6.  Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases.

Authors:  Ching-Chung Hsiao; Jih-Kai Yeh; Yan-Rong Li; Wei-Chiao Sun; Pei-Yi Fan; Chieh-Li Yen; Jung-Sheng Chen; Chihung Lin; Kuan-Hsing Chen
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

7.  Effects of Statin Use in Advanced Chronic Kidney Disease Patients.

Authors:  Tao-Min Huang; Vin-Cent Wu; Yu-Feng Lin; Jian-Jhong Wang; Chih-Chung Shiao; Likwang Chen; Shih-Chieh Jeff Chueh; Eric Chueh; Shao-Yu Yang; Tai-Shuan Lai; Shuei-Liong Lin; Tzong-Shinn Chu; Kwan-Dun Wu
Journal:  J Clin Med       Date:  2018-09-17       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.